Moody Aldrich Partners LLC Has $3.22 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Moody Aldrich Partners LLC decreased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,988 shares of the medical equipment provider’s stock after selling 2,383 shares during the quarter. Moody Aldrich Partners LLC owned about 0.05% of Lantheus worth $3,219,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in LNTH. Wilmington Savings Fund Society FSB acquired a new position in shares of Lantheus in the third quarter valued at approximately $25,000. Signaturefd LLC boosted its stake in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares during the period. UMB Bank n.a. boosted its stake in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares during the period. GAMMA Investing LLC boosted its stake in shares of Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after buying an additional 146 shares during the period. Finally, Kathleen S. Wright Associates Inc. bought a new stake in shares of Lantheus in the third quarter valued at approximately $51,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on LNTH shares. The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target for the company. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Truist Financial reiterated a “buy” rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Lantheus presently has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Price Performance

NASDAQ LNTH opened at $91.13 on Wednesday. The business has a fifty day moving average price of $91.78 and a two-hundred day moving average price of $100.12. Lantheus Holdings, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $126.89. The stock has a market capitalization of $6.34 billion, a PE ratio of 15.16 and a beta of 0.46.

Insiders Place Their Bets

In other news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.